Latest News - Psoriasis

Thursday, August 16, 2018

Ortho Dermatologics Resubmits NDA for Duobrii Lotion

Ortho Dermatologics, a division of Bausch Health Companies Inc., has resubmitted a New Drug Application (NDA) to the FDA for Duobrii™ (halobetasol propionate and tazarotene; …

Read the full story

Tuesday, August 14, 2018

Burt’s Bees Nature-Based Sensitive Skin Care Outperforms MD-Recommended Regimen

Burt’s Bees nature-based sensitive skin regimen is well-tolerated as well as clinically and statistically superior to a leading dermatologist-recommended synthetic regimen, according to a s…

Read the full story

Monday, August 13, 2018

Escalier Biosciences’ Doses First PsO Patient with ESR-114; Announces Clinical Advisory Board

The first patient has been dosed in a Phase 1/2a study evaluating Escalier Biosciences’ ESR-114 topical gel for mild-to-moderate psoriasis. "The initiation of this study represents a sig…

Read the full story

Friday, August 03, 2018

Almirall to Acquire Allergan’s US Medical Dermatology Unit

Almirall is acquiring a portfolio of five products from Allergan’s Medical Dermatology unit in the United States, conditional to the clearance by the relevant authorities. The portfolio includes…

Read the full story

Tuesday, July 31, 2018

LEO Pharma to Acquire Bayer Prescription Dermatology Business

LEO Pharma has entered into a definitive agreement to buy Bayer's global prescription dermatology unit. The portfolio to be acquired includes branded topical prescription treatments for acne, fung…

Read the full story

Monday, July 30, 2018

Experimental Drug May Reverse Hair Loss, Hair Whitening and Skin Inflammation

An experimental drug can successfully reverse hair loss, hair whitening and skin inflammation linked by previous studies to human diets heavy in fat and cholesterol, according to a new Johns Hopkins s…

Read the full story

Thursday, July 26, 2018

Link Between Diet and Skin Disease Takes Center Stage at Summer AAD

Dermatologists must help patients determine if there are any foods that may cause their skin condition to flare and provide evidence-based recommendations about next steps. “People looki…

Read the full story

Friday, July 20, 2018

Game On: Head-to-head Trials to Enhance Competition in PsO Market

An increase in head-to-head trials will enhance the competition within the psoriasis market, according to GlobalData. The first major biologics that were released were anti-tumor necrosis factor (a…

Read the full story

Monday, July 02, 2018

XELJANZ Receives EU Marketing Authorization for Adults with Active PsA

The European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adul…

Read the full story

Tuesday, June 26, 2018

LEO Pharma and Advancing Innovation in Dermatology Partner to Help Finance Accelerator Fund

LEO Pharma and its Boston-based R&D innovation unit LEO Science & Tech Hub, and Advancing Innovation in Dermatology (AID) will each contribute $500,000 into the recently created Advancing Inno…

Read the full story

Tuesday, June 26, 2018

UVBioTek Launches POLY Go Portable LED Light Therapy

UVBioTek has launched a new line of hand-held LED therapy products that support their newest brand, POLY LED Light Therapy. The mobile hand-held products, named “POLY Go”, use multiple wav…

Read the full story

Thursday, June 21, 2018

FDA-Approved Label Update: Cosentyx Inhibits Progression of Joint Structural Damage in PsA

The US FDA has approved a label update for Cosentyx® (secukinumab) from Novartis, including data that show the treatment significantly slows the progression of joint structural damage at Week 24 v…

Read the full story

Monday, June 18, 2018

Valeant: FDA Issues Complete Response Letter for Duobrii

Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. has received a Complete Response Letter (CRL) from the US FDA regarding the company's New Drug Application …

Read the full story

Wednesday, June 06, 2018

Luma Therapeutics Launches Novel illuvinate Phototherapy System

Luma Therapeutics has launched illuvinate as an innovative and modern twist on the Goeckerman regimen. By combining a narrowband UVB LED light with patented hydrogels containing coal tar micro-globule…

Read the full story

Tuesday, May 29, 2018

FDA Approves Cimzia for Moderate to Severe Plaque Psoriasis

The FDA has approved extending the label for UCB's Cimzia (certolizumab pegol) to include a new indication in adults with moderate to severe plaque psoriasis. Cimzia is indicated for the treatment…

Read the full story
Load More